Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009

P. Ljungman; M. Bregni; M. Brune; J. Cornelissen; T. de Witte; G. Dini; H. Einsele; H. B. Gaspar; A. Gratwohl; J. R. Passweg; C. Peters; Vanderson Rocha; R. Saccardi; H. Schouten; Anna Sureda; A. Tichelli; A. Velardi; Dietger W. Niederwieser

doi:10.1038/bmt.2009.141

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009

P. Ljungman^*, M. Bregni, M. Brune, J. Cornelissen, T. de Witte, G. Dini, H. Einsele, H. B. Gaspar, A. Gratwohl, J. R. Passweg, C. Peters, Vanderson Rocha, R. Saccardi, H. Schouten, Anna Sureda, A. Tichelli, A. Velardi, Dietger W. Niederwieser

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

97 Citations (Web of Science)

Abstract

The European Group for Blood and Marrow Transplantation regularly publishes special reports on the current practice of haematopoietic SCT for haematological diseases, solid tumours and immune disorders in Europe. Major changes have occurred since the first report was published. HSCT today includes grafting with allogeneic and autologous stem cells derived from BM, peripheral blood and cord blood. With reduced-intensity conditioning regimens in allogeneic transplantation, the age limit has increased, permitting the inclusion of older patients. New indications have emerged, such as autoimmune disorders and AL amyloidosis for autologous HSCT and solid tumours, myeloproliferative syndromes and specific subgroups of lymphomas for allogeneic transplants. The introduction of alternative therapies, such as imatinib for CML, has challenged well-established indications. An updated report with revised tables and operating definitions is presented.

Original language	English
Pages (from-to)	219-234
Journal	Bone Marrow Transplantation
Volume	45
Issue number	2
DOIs	https://doi.org/10.1038/bmt.2009.141
Publication status	Published - Feb 2010

Keywords

haematopoietic SCT
indications
recommendations
Europe

Access to Document

10.1038/bmt.2009.141

Cite this

Ljungman, P., Bregni, M., Brune, M., Cornelissen, J., de Witte, T., Dini, G., Einsele, H., Gaspar, H. B., Gratwohl, A., Passweg, J. R., Peters, C., Rocha, V., Saccardi, R., Schouten, H., Sureda, A., Tichelli, A., Velardi, A., & Niederwieser, D. W. (2010). Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplantation, 45(2), 219-234. https://doi.org/10.1038/bmt.2009.141

@article{79b4cadf7edc439db71501d2a4344e03,

title = "Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009",

abstract = "The European Group for Blood and Marrow Transplantation regularly publishes special reports on the current practice of haematopoietic SCT for haematological diseases, solid tumours and immune disorders in Europe. Major changes have occurred since the first report was published. HSCT today includes grafting with allogeneic and autologous stem cells derived from BM, peripheral blood and cord blood. With reduced-intensity conditioning regimens in allogeneic transplantation, the age limit has increased, permitting the inclusion of older patients. New indications have emerged, such as autoimmune disorders and AL amyloidosis for autologous HSCT and solid tumours, myeloproliferative syndromes and specific subgroups of lymphomas for allogeneic transplants. The introduction of alternative therapies, such as imatinib for CML, has challenged well-established indications. An updated report with revised tables and operating definitions is presented.",

keywords = "haematopoietic SCT, indications, recommendations, Europe",

author = "P. Ljungman and M. Bregni and M. Brune and J. Cornelissen and {de Witte}, T. and G. Dini and H. Einsele and Gaspar, {H. B.} and A. Gratwohl and Passweg, {J. R.} and C. Peters and Vanderson Rocha and R. Saccardi and H. Schouten and Anna Sureda and A. Tichelli and A. Velardi and Niederwieser, {Dietger W.}",

year = "2010",

month = feb,

doi = "10.1038/bmt.2009.141",

language = "English",

volume = "45",

pages = "219--234",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "2",

}

Ljungman, P, Bregni, M, Brune, M, Cornelissen, J, de Witte, T, Dini, G, Einsele, H, Gaspar, HB, Gratwohl, A, Passweg, JR, Peters, C, Rocha, V, Saccardi, R, Schouten, H, Sureda, A, Tichelli, A, Velardi, A & Niederwieser, DW 2010, 'Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009', Bone Marrow Transplantation, vol. 45, no. 2, pp. 219-234. https://doi.org/10.1038/bmt.2009.141

TY - JOUR

T1 - Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009

AU - Ljungman, P.

AU - Bregni, M.

AU - Brune, M.

AU - Cornelissen, J.

AU - de Witte, T.

AU - Dini, G.

AU - Einsele, H.

AU - Gaspar, H. B.

AU - Gratwohl, A.

AU - Passweg, J. R.

AU - Peters, C.

AU - Rocha, Vanderson

AU - Saccardi, R.

AU - Schouten, H.

AU - Sureda, Anna

AU - Tichelli, A.

AU - Velardi, A.

AU - Niederwieser, Dietger W.

PY - 2010/2

Y1 - 2010/2

N2 - The European Group for Blood and Marrow Transplantation regularly publishes special reports on the current practice of haematopoietic SCT for haematological diseases, solid tumours and immune disorders in Europe. Major changes have occurred since the first report was published. HSCT today includes grafting with allogeneic and autologous stem cells derived from BM, peripheral blood and cord blood. With reduced-intensity conditioning regimens in allogeneic transplantation, the age limit has increased, permitting the inclusion of older patients. New indications have emerged, such as autoimmune disorders and AL amyloidosis for autologous HSCT and solid tumours, myeloproliferative syndromes and specific subgroups of lymphomas for allogeneic transplants. The introduction of alternative therapies, such as imatinib for CML, has challenged well-established indications. An updated report with revised tables and operating definitions is presented.

AB - The European Group for Blood and Marrow Transplantation regularly publishes special reports on the current practice of haematopoietic SCT for haematological diseases, solid tumours and immune disorders in Europe. Major changes have occurred since the first report was published. HSCT today includes grafting with allogeneic and autologous stem cells derived from BM, peripheral blood and cord blood. With reduced-intensity conditioning regimens in allogeneic transplantation, the age limit has increased, permitting the inclusion of older patients. New indications have emerged, such as autoimmune disorders and AL amyloidosis for autologous HSCT and solid tumours, myeloproliferative syndromes and specific subgroups of lymphomas for allogeneic transplants. The introduction of alternative therapies, such as imatinib for CML, has challenged well-established indications. An updated report with revised tables and operating definitions is presented.

KW - haematopoietic SCT

KW - indications

KW - recommendations

KW - Europe

U2 - 10.1038/bmt.2009.141

DO - 10.1038/bmt.2009.141

M3 - Article

C2 - 19584824

VL - 45

SP - 219

EP - 234

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -